Embolic stroke of undetermined source (ESUS): clinical features
Evidence-based neurology checklist on embolic stroke of undetermined source (esus): clinical features: Demographic features ESUS accounts for about a third of TIAs and ischaemic strokes There is a higher risk in males There are usually no associated atherosclerosis risk factors There is a high…
Demographic features
- ESUS accounts for about a third of TIAs and ischaemic strokes
- There is a higher risk in males
- There are usually no associated atherosclerosis risk factors
- There is a high risk of recurrent stroke
Diagnostic criteria
Predictors of recurrence
References
- Li L, Yiin GS, Geraghty OC, Schulz UG, Kuker W, Mehta Z, Rothwell PM; Oxford Vascular Study. Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study. Lancet Neurol 2015; 14:903-913.
- Hart RG, Diener HC, Coutts SB, et al; Cryptogenic Stroke/ESUS International Working Group. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol 2014; 13:429-438.
- Nouh A, Hussain M, Mehta T, Yaghi S. Embolic strokes of unknown source and cryptogenic stroke: implications in clinical practice. Front Neurol 2016; 7:37.
- Hart RG, Veltkamp RC, Sheridan P, et al; NAVIGATE ESUS Investigators. Predictors of recurrent ischemic stroke in patients with embolic strokes of undetermined source and effects of rivaroxaban versus aspirin according to risk status: the NAVIGATE ESUS trial. J Stroke Cerebrovasc Dis 2019. pii: S1052-3057(19)30234-4 (Epub ahead of print).
- Ntaios G, Georgiopoulos G, Perlepe K, et al. A tool to identify patients with embolic stroke of undetermined source at high recurrence risk. Neurology 2019; pii: 10.1212/WNL.0000000000008571 (Epub ahead of print).
